Clinical trials: Keratoconjunctivitis Sicca
- Condition Keratoconjunctivitis Sicca
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Sjogren's Syndrome
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
The primary objective of this study is to assess the efficacy of filgotinib, lanraplenib, and tirabrutinib in adults with active Sjogren's Syndrome (SjS).
- Trial name
- NCT03100942
- Testing
- Lanraplenib, Filgotinib, Tirabrutinib
- Where
- 53 sites in United States, Poland and 2 more
- Volunteers
- 152 people
- Sponsor
- Gilead Sciences
Dry Eye Disease
A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye
The purpose of the study is to evaluate the safety and efficacy of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye.
- Trial name
- NCT01743729
- Testing
- Lifitegrast
- Where
- 31 sites in United States
- Volunteers
- 720 people
- Sponsor
- Shire
Dry Eye Disease
A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes
The purpose of this study is to evaluate the percentage of ocular adverse events reported in subjects with dry eye disease (DED) between the intervention arm (0.003% AR-15512) and control arm (REFRESH® Classic).
- Trial name
- NCT06660290
- Testing
- 0.003% AR-15512 ophthalmic solution, Artificial tears
- Where
- 6 sites in United States
- Volunteers
- 55 people
- Sponsor
- Alcon Research
Meibomian Gland Dysfunction
Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction
The objective of this study is to assess the safety and efficacy of testosterone 0.03% ophthalmic solution compared to vehicle for the treatment of meibomian gland dysfunction.
- Trial name
- NCT00755183
- Testing
- testosterone ophthalmic solution, vehicle of testosterone ophthalmic solution
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- ORA, Inc.
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 1 (NCT02813265)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 60 sites in United States
- Volunteers
- 918 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Eye Dryness
Comparison of Two Marketed Lenses in a Controlled Environment
This study is comparing two silicone hydrogel contact lenses in a controlled environment for identification of characteristics associated to vision.
- Trial name
- NCT02212301
- Testing
- senofilcon A, lotrafilcon B
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Dry Eye
Acute Comfort and Blur of Systane Ultra and Systane
To evaluate drop comfort, acceptability, preference and blue profile between two marketed artificial tears in both dry eyes and non-dry eye patient population.
- Trial name
- NCT00748865
- Testing
- Systane Ultra Lubricant Eye Drops, Systane Lubricant Eye Drops
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Alcon Research
Dry Eye
Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye
The purpose of this study is to evaluate efficacy and safety of the ophthalmic solution PRO-148 in the ocular surface of patients with mild to moderate dry eye compared with ophthalmic solution Systane®
- Trial name
- NCT01657253
- Testing
- PRO-148, Systane
- Where
- Mexico
- Volunteers
- 183 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Syndromes
Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®
This study will evaluate the efficacy of Restasis® in participants with dry eye disease who engage in electronic visual tasking.
- Trial name
- EMPOWER (NCT02554981)
- Testing
- Cyclosporine 0.05% Ophthalmic Emulsion
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Allergan
Dry Eye Syndromes
Dose-response Study of OPC-12759 Ophthalmic Suspension
The purpose of this study is to evaluate the dose-response of OPC-12759 ophthalmic suspension in dry eye patients.
- Trial name
- NCT00234078
- Testing
- 0.5% OPC-12759, 1% OPC-12759, 2% OPC-12759
- Where
- Japan
- Volunteers
- 290 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Keratoconjunctivitis Sicca
An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)
- Trial name
- NCT02845674
- Testing
- OTX-101 0.09%
- Volunteers
- 258 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Dry Eye Syndrome
Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining
The purpose of this study is to compare Systane® ULTRA lubricant eye drops to OPTIVE® lubricating eye drops for ocular surface staining within dry eye subjects and to evaluate the safety of Systane® ULTRA after 3 months of use.
- Trial name
- NCT01863368
- Testing
- Preservative-free saline solution eyedrops, Systane® ULTRA lubricant eyedrops, OPTIVE® lubricating eyedrops
- Volunteers
- 105 people
- Sponsor
- Alcon Research
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease.
- Trial name
- NCT05586152
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Invirsa, Inc.
Blepharitis, Meibomianitis
Treatment of Patients With Blepharitis and Facial Rosacea
To determine the safety and efficacy of sub-antimicrobial dose COL-101 in the treatment of patients who have both blepharitis and facial rosacea
- Conditions
- Blepharitis, Meibomianitis, Dry Eye
- Trial name
- NCT00560703
- Testing
- COL-101 (doxycycline, USP) capsules
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- Galderma R&D
Chronic Graft-versus-host Disease
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.
- Trial name
- DROPS-2 (NCT02040623)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rigel Pharmaceuticals
Sjögren's Syndrome
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's syndrome as measured by the change from…
- Trial name
- NCT02843659
- Testing
- BMS-931699, BMS-986142
- Where
- 34 sites in United States, Australia and 9 more
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Dry Eye Syndromes
Late Phase 2 Study of OPC-12759 Ophthalmic Suspension
The purpose of this study is to evaluate the dose-response of OPC-12759 suspension in dry eye patients
- Trial name
- NCT00475319
- Testing
- 1% OPC-12759 ophthalmic suspension, 2% OPC-12759 ophthalmic suspension
- Where
- 6 sites in Japan
- Volunteers
- 308 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Dry Eye Disease
A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye
The purpose of this study is to evaluate the efficacy and safety of SI-614 ophthalmic solution compared with placebo in patients with dry eye
- Trial name
- SIDE (NCT05411367)
- Testing
- SI-614
- Where
- 6 sites in United States
- Volunteers
- 232 people
- Sponsor
- Seikagaku Corporation
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
This study will evaluate the safety and efficacy of OPTIVE® MD for ocular surface integrity in symptomatic dry eye condition in absence of obvious eye-lid inflammation.
- Trial name
- NCT00987727
- Testing
- carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD), sodium hyaluronate 0.18% (VISMED® Multi)
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Allergan
Dry Eye Syndromes
An Open-Label, Multi-Center, Clinical Study Evaluating the Effect of the NDE L68 StableFit® Punctal Plug on the Tear Lake
To evaluate the effect of the NDE L68 StableFit® punctal plug on the tear lake.
- Trial name
- NCT04280653
- Testing
- NDE L68 StableFit® Punctal Plug
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Mati Therapeutics Inc.